Steinbeis Transfercenter "Immunoproteasome Drug Targeting"

Mission

In 2009 we identified the immunoproteasome as a new drug target for immunosuppressive
therapy in autoimmunity (Nature Medicine 15:781). We work on the validation and
charcterization of the immunoproteasome as a drug target. We test new inhibitors
of the immunoproteasome subunits and determine their specificity and function in
preclinical models of autoimmunity, cancer, and avoidance of transplant rejection.

Our services

  • Immunoproteasome purification and functional testing
  • Testing of proteasome subunit composition on two-dimensional gels
  • Validation and selectivity determination of immunoproteasome inhibitors
  • Preclinical models of autoimmunity (diabetes, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease)
  • Analysis of T helper cell differentiation in vitro and in vivo
  • Analysis of mice deficient for all subunits of the immunoproteasome
  • In vivo tests of T cell responses in models of viral and bacterial infection